Engineering Nanomedicine for Immune Modulation: From Antigen Delivery to Immune Checkpoint Synergy

Nanomedicine has emerged as a powerful platform for immune modulation, enabling precise strategies to enhance cancer immunotherapy, vaccines, and tolerance induction. Nanoparticles, including lipid, polymeric, and hybrid systems, facilitate efficient antigen delivery, promote cross-presentation, and enhance adaptive immune priming. In combination with immune checkpoint inhibitors, nanocarriers improve tumor localization, reduce systemic toxicity, and allow co-delivery of antigens and adjuvants. For adoptive cell therapies such as CAR-T and CAR-NK, nanotechnology supports non-viral gene engineering, cytokine delivery, and tumor microenvironment remodeling to improve persistence and infiltration. Messenger RNA (mRNA) nanomedicine, proven during the COVID-19 pandemic, has rapidly expanded into oncology, enabling personalized neoantigen vaccines, tolerogenic approaches for autoimmunity, and new modalities such as self-amplifying RNA. Despite these advances, clinical translation is constrained by safety, immunogenicity, manufacturing scalability, and regulatory challenges. Addressing these requires robust analytical frameworks, standardized quality control, and biomarker-driven trial design. Emerging tools such as AI-guided lipid design, digital twins, and adaptive clinical models may accelerate clinical translation. By bridging antigen delivery, checkpoint synergy, adoptive cell therapies, and mRNA platforms, nanomedicine represents a unifying framework for next-generation immunotherapies with the potential to transform patient outcomes. .